DK3842456T3 - Monoklonalt Interleukin-31-antistof - Google Patents

Monoklonalt Interleukin-31-antistof Download PDF

Info

Publication number: DK3842456T3
Authority: DK; Denmark
Prior art keywords: antibody; interleukin; monoclonal; monoclonal interleukin
Prior art date: 2011-07-21

Application number

DK20194926.0T

Other languages

English (en)

Inventor

Gary F Bammert

Steven A Dunham

Original Assignee

Zoetis Services Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-21

Filing date

2012-07-05

Publication date

2024-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46704979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3842456(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-07-05 Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc

2024-10-28 Application granted granted Critical

2024-10-28 Publication of DK3842456T3 publication Critical patent/DK3842456T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK20194926.0T 2011-07-21 2012-07-05 Monoklonalt Interleukin-31-antistof DK3842456T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161510268P	2011-07-21	2011-07-21
EP17168574.6A EP3219729B1 (en)	2011-07-21	2012-07-05	Interleukin-31 monoclonal antibody

Publications (1)

Publication Number	Publication Date
DK3842456T3 true DK3842456T3 (da)	2024-10-28

Family

ID=46704979

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK19196963.3T DK3653645T3 (da)	2011-07-21	2012-07-05	Monoklonal interleukin-31-antistof
DK12748547.2T DK2734549T3 (da)	2011-07-21	2012-07-05	Monoklonalt antistof mod hunde-interleukin-31
DK24200176.6T DK4459282T3 (da)	2011-07-21	2012-07-05	Monoklonalt interleukin-31-antistof
DK20194926.0T DK3842456T3 (da)	2011-07-21	2012-07-05	Monoklonalt Interleukin-31-antistof

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
DK19196963.3T DK3653645T3 (da)	2011-07-21	2012-07-05	Monoklonal interleukin-31-antistof
DK12748547.2T DK2734549T3 (da)	2011-07-21	2012-07-05	Monoklonalt antistof mod hunde-interleukin-31
DK24200176.6T DK4459282T3 (da)	2011-07-21	2012-07-05	Monoklonalt interleukin-31-antistof

Country Status (25)

Country	Link
US (6)	US8790651B2 (da)
EP (5)	EP3842456B1 (da)
JP (1)	JP6022563B2 (da)
KR (2)	KR101613024B1 (da)
CN (2)	CN105504059B (da)
AR (1)	AR087281A1 (da)
AU (2)	AU2012285432C1 (da)
BR (1)	BR112014001407A8 (da)
CA (2)	CA2926379A1 (da)
CY (2)	CY1119475T1 (da)
DK (4)	DK3653645T3 (da)
ES (4)	ES2993120T3 (da)
FI (2)	FI3653645T3 (da)
HR (4)	HRP20241388T1 (da)
HU (4)	HUE034282T2 (da)
LT (4)	LT3842456T (da)
ME (1)	ME02837B (da)
MX (2)	MX377475B (da)
PL (4)	PL3842456T3 (da)
PT (4)	PT2734549T (da)
RS (4)	RS56268B1 (da)
SI (4)	SI3842456T1 (da)
UY (1)	UY34206A (da)
WO (1)	WO2013011407A1 (da)
ZA (1)	ZA201400768B (da)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA013677B1 (ru) *	2002-11-15	2010-06-30	Генмаб А/С	Человеческие моноклональные антитела против cd25 и их применение
FI3345607T3 (fi) *	2006-12-29	2022-11-30		Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
HRP20131113T1 (hr) *	2007-02-16	2014-01-17	Merrimack Pharmaceuticals, Inc.	Protutijela protiv erbb3 i njihova uporaba
AU2008333131B2 (en) *	2007-12-07	2013-10-24	Merck Serono S/A	Humanized antibody molecules specific for IL-31
SMT202000095T1 (it) *	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
JP6324720B2 (ja)	2010-06-18	2018-05-16	エックスバイオテク, インコーポレイテッドXbiotech, Inc.	関節炎治療
LT2647707T (lt)	2010-11-30	2018-11-12	Chugai Seiyaku Kabushiki Kaisha	Citotoksiškumą indukuojantis terapinis agentas
EP4086338A1 (en)	2011-03-17	2022-11-09	Minerva Biotechnologies Corporation	Method for making pluripotent stem cells
US8790651B2 (en)	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
EP2888277A4 (en)	2012-08-21	2016-05-18	Ortho Clinical Diagnostics Inc	ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
PT2888593T (pt)	2012-08-21	2018-12-12	Janssen Pharmaceutica Nv	Anticorpos contra risperidona e utilizações dos mesmos
EP3590537A1 (en) *	2012-09-26	2020-01-08	Julius-Maximilians-Universität Würzburg	Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
CN107880126B (zh) *	2012-12-21	2021-03-30	西雅图基因公司	抗ntb-a抗体及相关组合物和方法
WO2014100689A1 (en) *	2012-12-21	2014-06-26	Aveo Pharmaceuticals, Inc.	Anti-gdf15 antibodies
CA2944989A1 (en) *	2013-04-08	2014-10-16	Cytodyn Inc.	Felinized antibodies and methods of treating retroviral infections in felines
TWI682781B (zh)	2013-07-11	2020-01-21	美商再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CA2918795A1 (en) *	2013-07-25	2015-01-29	Cytomx Therapeutics, Inc.	Multispecific antibodies, multispecific activatable antibodies and methods of using the same
LT3065774T (lt) *	2013-11-06	2021-09-10	Janssen Biotech, Inc.	Anti-ccl17 antikūnai
US11072647B2 (en) *	2013-12-19	2021-07-27	Onsejo Nacional DE Investigation Cientiticay Tecnica	TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
CA2932515C (en)	2013-12-20	2023-08-01	Intervet International B.V.	Caninized antibodies
ES2923641T3 (es) *	2013-12-30	2022-09-29	Epimab Biotherapeutics Inc	Inmunoglobulina con Fabs en tándem y usos de la misma
EP3102939A4 (en) *	2014-02-05	2018-02-28	Dana-Farber Cancer Institute, Inc.	AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
CN106536551B (zh) *	2014-02-06	2021-04-16	X4制药(奥地利)有限责任公司	大肠杆菌特异性抗体序列
DK3122775T3 (da) *	2014-03-26	2020-02-03	Univ Wuerzburg J Maximilians	Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
EP3157952B1 (en) *	2014-06-20	2021-12-22	Aveo Pharmaceuticals, Inc.	Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US9212225B1 (en) *	2014-07-01	2015-12-15	Amphivena Therapeutics, Inc.	Bispecific CD33 and CD3 binding proteins
JP6843736B2 (ja) *	2014-07-16	2021-03-17	トランジェーヌＴｒａｎｓｇｅｎｅ	腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
EP3197493B1 (en) *	2014-09-25	2021-03-10	Aveo Pharmaceuticals Inc.	Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
MA40824A (fr) *	2014-10-22	2017-08-29	Saiba Gmbh	Particules de cmv de type virus modifié
WO2016075612A1 (en) *	2014-11-12	2016-05-19	Rinat Neuroscience Corp.	Inhibitory chimeric antigen receptors
WO2016104657A1 (ja) *	2014-12-26	2016-06-30	橋本正	癌治療剤
KR20170105558A (ko)	2015-01-30	2017-09-19	각코우호우징 사이타마이카다이가쿠	항 alk2 항체
EP3258959A4 (en) *	2015-02-22	2018-10-17	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind cd137
NZ736026A (en) *	2015-03-31	2023-02-24	Medimmune Ltd	A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
US11424061B2 (en) *	2015-04-14	2022-08-23	Hanchett Entry Systems, Inc.	Solenoid assembly actuation using resonant frequency current controller circuit
ES3036076T3 (en)	2015-04-14	2025-09-12	Chugai Pharmaceutical Co Ltd	Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2016167263A1 (ja)	2015-04-14	2016-10-20	中外製薬株式会社	Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
KR102537102B1 (ko)	2015-05-29	2023-05-25	엠피베나 테라퓨틱스, 인크.	이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
CN106336459B (zh) *	2015-07-13	2020-12-08	三生国健药业（上海）股份有限公司	抗人白细胞介素-17a单克隆抗体、其制备方法和应用
AU2016333538B2 (en)	2015-10-02	2022-03-31	Julius-Maximilians-Universität Würzburg	GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
TW202417497A (zh)	2015-10-12	2024-05-01	美商再生元醫藥公司	活化瘦素受體的抗原結合蛋白
CA3004804A1 (en) *	2015-11-17	2017-05-26	Jiangsu Hengrui Medicine Co., Ltd.	Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof
WO2017106501A1 (en)	2015-12-17	2017-06-22	Janssen Pharmaceutica Nv	Antibodies to risperidone and use thereof
EP3402516A4 (en) *	2016-01-12	2020-01-08	Palleon Pharmaceuticals Inc.	USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
MX394254B (es) *	2016-04-27	2025-03-24	Benchmark Animal Health Ltd	Composiciones para el tratamiento de dermatitis atópica canina y sus usos.
CN113372446A (zh) *	2016-06-08	2021-09-10	苏州康乃德生物医药有限公司	用于结合白细胞介素4受体的抗体
CN110381988A (zh) *	2016-06-15	2019-10-25	诺华股份有限公司	使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
AU2017297506A1 (en) *	2016-07-14	2019-02-21	Bristol-Myers Squibb Company	Antibodies against TIM3 and uses thereof
EP4442323A3 (en)	2016-09-01	2025-01-01	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
RU2759334C2 (ru) *	2016-09-21	2021-11-12	Нексткьюр, Инк.	Антитела против siglec-15 и способы их применения
CN118359704A (zh) *	2016-10-19	2024-07-19	英温拉公司	抗体构建体
CN110167965A (zh)	2016-11-08	2019-08-23	瑞泽恩制药公司	拮抗瘦素受体的抗原结合蛋白
EP3538558A4 (en)	2016-11-09	2020-07-15	North Carolina State University	TREATMENT OF ALLERGIC DISEASES USING CHIMERIC PROTEIN
KR20220051269A (ko) *	2016-12-21	2022-04-26	메레오 바이오파마 3 리미티드	불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
US11680101B2 (en) *	2017-01-27	2023-06-20	Kymab Limited	Anti-OPG antibodies
KR20190117579A (ko) *	2017-02-16	2019-10-16	엑스바이오테크, 인크.	화농성 한선염의 치료
WO2018156250A1 (en) *	2017-02-21	2018-08-30	Remd Biotherapeutics, Inc.	Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
WO2018156180A1 (en)	2017-02-24	2018-08-30	Kindred Biosciences, Inc.	Anti-il31 antibodies for veterinary use
WO2018156367A1 (en) *	2017-02-24	2018-08-30	Kindred Biosciences, Inc.	Anti-il31 antibodies for veterinary use
EP3592379B1 (en) *	2017-03-31	2024-04-24	Cellectis SA	Universal anti-cd22 chimeric antigen receptor engineered immune cells
SG11201908813QA (en) *	2017-04-13	2019-10-30	Aduro Biotech Holdings Europe B V	Anti-sirp alpha antibodies
CN117018189A (zh) *	2017-05-26	2023-11-10	葛兰素史密斯克莱知识产权发展有限公司	生物制药组合物和相关方法
CN110267989B (zh) *	2017-06-01	2023-04-04	江苏恒瑞医药股份有限公司	抗cd40抗体、其抗原结合片段及其医药用途
CA3068038A1 (en) *	2017-06-28	2019-01-03	Becton, Dickinson And Company	Sandwich-type assays using decreasing signal portions of dose response curve to measure analytes, including analytes at high concentration
TWI726228B (zh) *	2017-08-09	2021-05-01	國立臺灣大學	Ｃｄ１４拮抗分子用於治療癌症
EP3668893A4 (en) *	2017-08-16	2021-08-04	Dragonfly Therapeutics, Inc.	PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
EP3684795A1 (en) *	2017-09-21	2020-07-29	Imcheck Therapeutics SAS	Antibodies having specificity for btn2 and uses thereof
RU2698048C2 (ru) *	2017-10-03	2019-08-21	Закрытое Акционерное Общество "Биокад"	МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
IL321773A (en)	2017-10-14	2025-08-01	Cytomx Therapeutics Inc	Activatable antibodies and methods for preparing them
WO2019086694A1 (en)	2017-11-06	2019-05-09	Geert Mudde	Il31 antigen and vaccine
WO2019104157A1 (en) *	2017-11-21	2019-05-31	The University Of Vermont And State Agricultural College	Highly specific zika neutralizing human antibodies
CA3085318A1 (en) *	2017-12-11	2019-06-20	Ubi Ip Holdings	Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
MX2020006508A (es)	2017-12-18	2020-09-17	Regeneron Pharma	Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
CN109957026A (zh) *	2017-12-22	2019-07-02	成都恩沐生物科技有限公司	共价多特异性抗体
KR102813913B1 (ko)	2018-01-12	2025-05-30	브리스톨-마이어스 스큅 컴퍼니	Tim3에 대한 항체 및 그의 용도
TWI822728B (zh) *	2018-01-31	2023-11-21	加藤元一	含有il-6抑制劑的哮喘治療劑
CA3090236A1 (en)	2018-02-08	2019-08-15	Dragonfly Therapeutics, Inc.	Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en)	2018-02-08	2020-09-29	Dragonfly Therapeutics Inc	Antibody variable domains targeting the nkg2d receptor
SG11202007558YA (en) *	2018-02-09	2020-09-29	Nestle Skin Health Sa	Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
KR102832460B1 (ko)	2018-02-20	2025-07-11	드래곤플라이 쎄라퓨틱스, 인크.	Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
JP7497293B2 (ja)	2018-03-16	2024-06-10	ゾエティス・サービシーズ・エルエルシー	インターロイキン－３１に対するペプチドワクチン
KR102828306B1 (ko) *	2018-03-16	2025-07-01	조에티스 서비시즈 엘엘씨	수의학적 용도를 위한 인터류킨-31 단클론성 항체
CN112236523A (zh) *	2018-03-16	2021-01-15	国立大学法人滋贺医科大学	降解和去除异常tdp-43的抗体片段
WO2019183437A1 (en)	2018-03-23	2019-09-26	North Carolina State University	Methods and compositions for antibody to high affinity receptor for ige
JP7420730B2 (ja)	2018-04-06	2024-01-23	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
AU2019267050B2 (en) *	2018-05-09	2024-09-12	Good T Cells, Inc.	Epitope of regulatory T cell surface antigen and antibody specifically binding thereto
EP3806885A2 (en) *	2018-06-13	2021-04-21	Kymab Limited	Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
TWI822815B (zh) *	2018-07-14	2023-11-21	財團法人生物技術開發中心	抗-人類ｐｄ-ｌ１之抗體及其用途
BR112021001693A2 (pt)	2018-08-03	2021-05-04	Chugai Seiyaku Kabushiki Kaisha	molécula de ligação ao antígeno contendo dois domínios de ligação ao antígeno q ligados entre si
US12161890B2 (en) *	2018-08-07	2024-12-10	Cz Biohub Sf, Llc	Antibodies against dengue virus and related methods
MA53293A (fr)	2018-08-08	2021-11-17	Dragonfly Therapeutics Inc	Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
MX2021001527A (es)	2018-08-08	2021-06-15	Dragonfly Therapeutics Inc	Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
EA202091888A1 (ru)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102715542B1 (ko) *	2018-08-20	2024-10-08	화이자 인코포레이티드	항-gdf15 항체, 조성물 및 사용 방법
SG11202101912UA (en) *	2018-09-28	2021-04-29	Chugai Pharmaceutical Co Ltd	Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
US20220267428A1 (en) *	2018-10-10	2022-08-25	The Board Of Trustees Of The Leland Stanford Junior University	BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
PE20212156A1 (es) *	2018-12-19	2021-11-09	United Biomedical Inc	Epitopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunogenos peptidicos inteticos
BR112021010374A2 (pt) *	2018-12-21	2021-08-24	23Andme, Inc.	Anticorpos anti-il-36 e métodos de uso dos mesmos
WO2020136096A1 (en) *	2018-12-29	2020-07-02	Berysol Gmbh	Selenium binding protein 1 detection from body fluids for diagnosis of peracute tissue damage
MX2021008144A (es)	2019-01-03	2021-10-13	Invetx Inc	Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
MX2021011141A (es) *	2019-03-21	2022-01-19	Regeneron Pharma	Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
SG11202110626SA (en) *	2019-03-27	2021-10-28	Umc Utrecht Holding Bv	Engineered iga antibodies and methods of use
CN114364693A (zh) *	2019-05-03	2022-04-15	新加坡保健服务私人有限公司	代谢性疾病的治疗和预防
CN110283246A (zh) *	2019-06-20	2019-09-27	长春西诺生物科技有限公司	一种抗猫细小病毒的猫源化基因工程抗体
JP7695228B2 (ja) *	2019-07-15	2025-06-18	インターベットインターナショナルベー．フェー．	ヒト及びイヌｃｔｌａ－４に対するイヌ化抗体
JP2022542275A (ja) *	2019-07-30	2022-09-30	キンドレッドバイオサイエンシズインコーポレイテッド	動物用パルボウイルス抗体
EP4013494A1 (en) *	2019-08-12	2022-06-22	Regeneron Pharmaceuticals, Inc.	Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
EP3820907A4 (en) *	2019-08-27	2022-05-04	Elpiscience (Suzhou) Biopharma, Ltd.	NOVEL ANTI-CD39 ANTIBODIES
CN114555121A (zh) *	2019-08-29	2022-05-27	金德雷德生物科学股份有限公司	兽用抗il31抗体
WO2021037007A1 (zh) *	2019-08-29	2021-03-04	荣昌生物制药(烟台)股份有限公司	抗pd-l1抗体及其应用
US20220340647A1 (en) *	2019-09-14	2022-10-27	Immundiagnostik Ag	Medicinal preparation for treating fibrosis with anti bsp antibodies
AU2020355027A1 (en)	2019-09-23	2022-04-21	Twist Bioscience Corporation	Antibodies that bind CD3 Epsilon
KR20220070514A (ko) *	2019-09-30	2022-05-31	얀센 파마슈티카 엔.브이.	소분자 조절제를 사용한 il-17 표적 결합 검정을 위한 조성물 및 방법
CN112569358B (zh) *	2019-09-30	2022-06-28	上海生物制品研究所有限责任公司	培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用
US11890353B2 (en) *	2019-10-15	2024-02-06	Northwestern University	Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
BR112022006590A2 (pt)	2019-11-20	2022-06-28	Chugai Pharmaceutical Co Ltd	Preparação contendo anticorpos
EP4071171B1 (en) *	2019-12-06	2025-06-25	Korea Atomic Energy Research Institute	Anti-tm4sf4 antibody and use thereof
AU2020398045A1 (en) *	2019-12-06	2022-06-09	Sotio Biotech A.S.	Humanized CLDN18.2 antibodies
KR20220110753A (ko) *	2019-12-10	2022-08-09	에이비엘바이오 주식회사	항-bcma/항-4-1bb 이중특이성 항체 및 그의 용도
MX2022007677A (es)	2019-12-20	2022-07-19	Intervet Int Bv	Anticuerpos para receptor alfa de interleucina-4 canino.
CA3161728A1 (en) *	2019-12-20	2021-06-24	Mohamad Morsey	Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
CN113134081A (zh) *	2020-01-20	2021-07-20	上海君实生物医药科技股份有限公司	抗btla抗体药物组合物及其用途
EP4110819A1 (en) *	2020-02-28	2023-01-04	Apexigen, Inc.	Anti-sirpa antibodies and methods of use
US11987640B2 (en) *	2020-04-07	2024-05-21	Fred Hutchinson Cancer Center	Anti-mesothelin antigen-binding molecules and uses thereof
US20230374114A1 (en) *	2020-04-16	2023-11-23	Dana-Farber Cancer Institute, Inc.	Coronavirus antibodies and methods of use thereof
BR112022020631A2 (pt) *	2020-04-17	2022-11-29	Zoetis Services Llc	Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula
US20230242635A1 (en) *	2020-04-17	2023-08-03	Zoetis Services Llc	Canine antibody variants
BR112022021450A2 (pt) *	2020-04-24	2022-12-27	Millennium Pharm Inc	O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
MX2022013944A (es)	2020-05-06	2022-11-30	Dragonfly Therapeutics Inc	Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
TWI800824B (zh) *	2020-05-08	2023-05-01	大陸商亘喜生物科技（上海）有限公司	一種抗cd19抗體的抗體及其製備和應用
EP4149969A1 (en)	2020-05-11	2023-03-22	Invetx, Inc.	Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20250154267A2 (en) *	2020-05-22	2025-05-15	Regeneron Pharmaceuticals, Inc.	Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
AU2021306179A1 (en)	2020-07-10	2023-03-02	Invetx Inc.	Compositions for increasing half-life of a therapeutic agent in felines and methods of use
MX2023001491A (es)	2020-08-05	2023-03-08	Synthekine Inc	Moleculas de union a gp130 y metodos de uso.
KR20250127176A (ko)	2020-08-05	2025-08-26	신테카인, 인크.	IL27Rα 결합 분자 및 사용 방법
WO2022031890A1 (en)	2020-08-05	2022-02-10	Synthekine, Inc.	Ifngr2 binding molecules and methods of use
WO2022032022A2 (en)	2020-08-05	2022-02-10	Synthekine, Inc.	Il10 receptor binding molecules and methods of use
US12122839B2 (en)	2020-08-05	2024-10-22	Synthekine, Inc.	IFNGR binding synthetic cytokines and methods of use
WO2022031871A1 (en)	2020-08-05	2022-02-10	Synthekine, Inc.	Compositions and methods related to il27 receptor binding
GB202012331D0 (en)	2020-08-07	2020-09-23	Petmedix Ltd	Therapeutic antibodies
FR3113458B1 (fr)	2020-08-21	2022-10-14	Purally	Composition comprenant au moins un flavonoide glycosyle et son utilisation en cosmetique ou dermatologie
EP4200019A1 (en) *	2020-08-21	2023-06-28	Genzyme Corporation	Fgfr3 antibodies and methods of use
MX2023003624A (es)	2020-09-28	2023-04-11	Zoetis Services Llc	Variantes de anticuerpos caninos.
PE20240110A1 (es)	2020-09-29	2024-01-22	Zoetis Services Llc	Variantes de anticuerpos felinos
WO2022079138A1 (en)	2020-10-15	2022-04-21	Intervet International B.V.	Caninized rat antibodies to canine interleukin-31 receptor alpha
MX2023004500A (es)	2020-10-19	2023-05-10	Zoetis Services Llc	Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos.
US11739137B2 (en) *	2020-10-30	2023-08-29	The Government Of The United States Of America, As Represented By The Secretary Of The Navy	Single domain antibodies to SARS-CoV-2 nucleocapsid protein
WO2022099090A1 (en) *	2020-11-06	2022-05-12	Xencor, Inc.	Heterodimeric antibodies that bind tgfbrii
AU2021383841A1 (en) *	2020-11-23	2023-06-22	Scout Bio, Inc.	Antigen-binding molecules and uses thereof
EP4263596A1 (en) *	2020-12-18	2023-10-25	Zoetis Services LLC	Mutations in feline antibody constant regions
AU2022214843A1 (en)	2021-01-28	2023-07-20	Zoetis Services Llc	Mutations in canine antibody constant regions
AU2022212600A1 (en)	2021-01-29	2023-08-17	Bayer Animal Health Gmbh	Vaccine composition for breaking self-tolerance
IL305266A (en) *	2021-02-17	2023-10-01	Gammadelta Therapeutics Ltd	Multispecific antibodies against variable TCR delta 1
BR112023016043A2 (pt)	2021-02-22	2023-12-05	Zoetis Services Llc	Modelo de prurido induzido por il-31 de cavalo
WO2022187539A1 (en)	2021-03-03	2022-09-09	Dragonfly Therapeutics, Inc.	Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CA3212599A1 (en) *	2021-03-22	2022-09-29	Novimmune S.A.	Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
IL305827A (en)	2021-03-22	2023-11-01	Novimmune Sa	Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
US12258406B2 (en) *	2021-03-24	2025-03-25	Twist Bioscience Corporation	Antibodies that bind CD3 Epsilon
US20250002590A1 (en) *	2021-04-23	2025-01-02	Astrazeneca Ab	Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
AU2022331122A1 (en)	2021-08-20	2024-02-15	Intervet International B.V.	Homodimer fusion proteins for treating atopic dermatitis
US20230192834A1 (en) *	2021-09-27	2023-06-22	Zoetis Services Llc	Anti- tgfb1,2,3 antibodies and therapeutic uses thereof
EP4448572A1 (en)	2021-12-16	2024-10-23	Intervet International B.V.	Caninized antibodies to canine interleukin-31 receptor alpha 1
EP4476256A1 (en)	2022-02-09	2024-12-18	Petmedix Ltd.	Therapeutic antibodies
EP4486387A1 (en)	2022-02-28	2025-01-08	Tridem Bioscience GmbH & Co KG	A conjugate consisting of or comprising at least a ss-glucan or a mannan
WO2024057096A1 (en)	2022-09-14	2024-03-21	Ceva Sante Animale	Treatment of atopic dermatitis using self-replicating rna expressing il-31
CN115505575B (zh) *	2022-11-16	2023-03-24	中国科学院天津工业生物技术研究所	两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用
WO2024170485A1 (en)	2023-02-13	2024-08-22	Intervet International B.V.	Canine antibodies to canine il-13
CN120897928A (zh)	2023-02-13	2025-11-04	英特维特国际股份有限公司	针对犬il-4的犬抗体
CN117186220A (zh) *	2023-07-20	2023-12-08	北京伟杰信生物科技有限公司	可结合白介素31的抗体或其抗原结合片段及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5350576A (en)	1991-09-13	1994-09-27	Mycogen Corporation	Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en)	1997-02-18	2001-02-27	Washington State University Research Foundation	ω-3 fatty acid desaturase
EP1082432A2 (en) *	1998-05-29	2001-03-14	Heska Corporation	Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
AU767172B2 (en)	1999-03-18	2003-11-06	Merck Patent Gmbh	Protein for blocking platelet adhesion
US6790639B2 (en)	2000-02-29	2004-09-14	Pfizer Inc.	Mammalian osteoregulins
DK1270595T3 (da) *	2000-03-03	2008-11-10	Kyowa Hakko Kogyo Kk	Anti-CCR4-antistof og dets fragment
KR100419555B1 (ko)	2000-05-29	2004-02-19	주식회사유한양행	비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US6818444B2 (en) *	2000-08-04	2004-11-16	Heska Corporation	Canine and feline proteins, nucleic acid molecules and uses thereof
US20030031671A1 (en)	2001-08-01	2003-02-13	Sydney Welt	Methods of treating colon cancer utilizing tumor-specific antibodies
US7261890B2 (en) *	2001-12-21	2007-08-28	Idexx Laboratories, Inc.	Methods for using canine immunoglobulin variable domains and caninized antibodies
EP1476541B1 (en)	2002-01-18	2008-07-16	ZymoGenetics, Inc.	Cytokine (zcytor17 ligand)
US20040208870A1 (en)	2003-01-30	2004-10-21	Medimmune, Inc.	Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
KR20060015602A (ko) *	2003-05-31	2006-02-17	마이크로메트 에이지	ＥｐＣＡＭ 에 대한 이중 특이성 항체를 포함하는약학조성물
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1671642A1 (en)	2004-12-15	2006-06-21	Universite D'angers	Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
ES2579758T3 (es)	2005-01-28	2016-08-16	Zymogenetics, Inc.	Preparaciones homogéneas de IL-31
WO2008021976A2 (en)	2006-08-09	2008-02-21	Baylor Research Institute	Anti-interferon alpha monoclonal antibodies and methods for use
WO2006088855A1 (en)	2005-02-14	2006-08-24	Zymogenetics, Inc.	Methods of treating skin disorders using an il-31ra antagonist
EP1856150A2 (en)	2005-02-14	2007-11-21	ZymoGenetics, Inc.	Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
WO2006104978A2 (en)	2005-03-25	2006-10-05	Curagen Corporation	Antibodies against the tenascin major antigens
US8101183B2 (en)	2005-05-06	2012-01-24	Zymogentics, Inc.	Variable region sequences of IL-31 monoclonal antibodies
JP5065253B2 (ja) *	2005-05-06	2012-10-31	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−３１モノクローナル抗体とその使用法
MX2008008831A (es)	2006-01-10	2009-03-04	Zymogenetics Inc	Metodos para tratar dolor e inflamacion en tejidos neuronales usando antagonistas il-31.
DK2594586T3 (da)	2006-09-01	2014-11-17	Zymogenetics Inc	Monoklonale il-31-antistoffer og fremgangsmåder til anvendelse heraf
PL2068921T3 (pl)	2006-10-19	2014-12-31	Csl Ltd	Przeciwciała o dużym powinowactwie będące antagonistami receptora alfa1 interleukiny 13
AU2008333131B2 (en) *	2007-12-07	2013-10-24	Merck Serono S/A	Humanized antibody molecules specific for IL-31
PT2384326E (pt)	2008-08-20	2014-06-09	Zoetis Llc	Compostos de pirrolo[2,3-d]pirimidina
US8337842B2 (en)	2008-09-04	2012-12-25	Vet Therapeutics, Inc.	Monoclonal antibodies
WO2011065935A1 (en)	2009-11-24	2011-06-03	Cornell University	Methods for monoclonal antibody production
WO2010117448A2 (en) *	2009-04-05	2010-10-14	Provenance Biopharmaceuticals Corp.	Chimeric immunocytokines and methods of use thereof
UY32948A (es)	2009-10-15	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2317730B1 (en)	2009-10-29	2015-08-12	Unify GmbH & Co. KG	Method and system to automatically change or update the configuration or setting of a communication system
SG10201501342UA (en)	2010-02-24	2015-04-29	Immunogen Inc	Folate receptor 1 antibodies and immunoconjugates and uses thereof
TR201802772T4 (tr) *	2010-11-17	2018-03-21	Chugai Pharmaceutical Co Ltd	Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
US8790651B2 (en)	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
AU2012288926A1 (en)	2011-07-22	2014-01-16	Glaxosmithkline Biologicals S.A.	PRAME purification
KR102828306B1 (ko) *	2018-03-16	2025-07-01	조에티스 서비시즈 엘엘씨	수의학적 용도를 위한 인터류킨-31 단클론성 항체

2012
- 2012-06-28 US US13/536,081 patent/US8790651B2/en active Active
- 2012-07-05 SI SI201232079T patent/SI3842456T1/sl unknown
- 2012-07-05 EP EP20194926.0A patent/EP3842456B1/en active Active
- 2012-07-05 PT PT127485472T patent/PT2734549T/pt unknown
- 2012-07-05 SI SI201231038T patent/SI2734549T1/sl unknown
- 2012-07-05 PT PT201949260T patent/PT3842456T/pt unknown
- 2012-07-05 CA CA2926379A patent/CA2926379A1/en not_active Abandoned
- 2012-07-05 MX MX2017008963A patent/MX377475B/es unknown
- 2012-07-05 HU HUE12748547A patent/HUE034282T2/en unknown
- 2012-07-05 KR KR1020147004364A patent/KR101613024B1/ko active Active
- 2012-07-05 HR HRP20241388TT patent/HRP20241388T1/hr unknown
- 2012-07-05 SI SI201231847T patent/SI3219729T1/sl unknown
- 2012-07-05 PT PT171685746T patent/PT3219729T/pt unknown
- 2012-07-05 RS RS20170846A patent/RS56268B1/sr unknown
- 2012-07-05 LT LTEP20194926.0T patent/LT3842456T/lt unknown
- 2012-07-05 ES ES19196963T patent/ES2993120T3/es active Active
- 2012-07-05 EP EP19196963.3A patent/EP3653645B1/en active Active
- 2012-07-05 DK DK19196963.3T patent/DK3653645T3/da active
- 2012-07-05 AU AU2012285432A patent/AU2012285432C1/en active Active
- 2012-07-05 PL PL20194926.0T patent/PL3842456T3/pl unknown
- 2012-07-05 MX MX2014000803A patent/MX349053B/es active IP Right Grant
- 2012-07-05 HR HRP20171198TT patent/HRP20171198T1/hr unknown
- 2012-07-05 CN CN201610117883.3A patent/CN105504059B/zh active Active
- 2012-07-05 FI FIEP19196963.3T patent/FI3653645T3/fi active
- 2012-07-05 PL PL19196963.3T patent/PL3653645T3/pl unknown
- 2012-07-05 PL PL17168574T patent/PL3219729T3/pl unknown
- 2012-07-05 HU HUE20194926A patent/HUE068973T2/hu unknown
- 2012-07-05 SI SI201232073T patent/SI3653645T1/sl unknown
- 2012-07-05 BR BR112014001407A patent/BR112014001407A8/pt not_active Application Discontinuation
- 2012-07-05 DK DK12748547.2T patent/DK2734549T3/da active
- 2012-07-05 CN CN201280046131.2A patent/CN103890009B/zh active Active
- 2012-07-05 RS RS20241255A patent/RS66170B1/sr unknown
- 2012-07-05 RS RS20241246A patent/RS66178B1/sr unknown
- 2012-07-05 ME MEP-2017-192A patent/ME02837B/me unknown
- 2012-07-05 JP JP2014520753A patent/JP6022563B2/ja active Active
- 2012-07-05 ES ES12748547.2T patent/ES2638340T3/es active Active
- 2012-07-05 PT PT191969633T patent/PT3653645T/pt unknown
- 2012-07-05 HR HRP20241528TT patent/HRP20241528T1/hr unknown
- 2012-07-05 HU HUE17168574A patent/HUE051068T2/hu unknown
- 2012-07-05 WO PCT/IB2012/053450 patent/WO2013011407A1/en not_active Ceased
- 2012-07-05 LT LTEP19196963.3T patent/LT3653645T/lt unknown
- 2012-07-05 LT LTEP17168574.6T patent/LT3219729T/lt unknown
- 2012-07-05 RS RS20201227A patent/RS60924B1/sr unknown
- 2012-07-05 EP EP17168574.6A patent/EP3219729B1/en not_active Revoked
- 2012-07-05 DK DK24200176.6T patent/DK4459282T3/da active
- 2012-07-05 FI FIEP20194926.0T patent/FI3842456T3/fi active
- 2012-07-05 EP EP12748547.2A patent/EP2734549B1/en not_active Revoked
- 2012-07-05 CA CA2842475A patent/CA2842475C/en active Active
- 2012-07-05 ES ES20194926T patent/ES2994801T3/es active Active
- 2012-07-05 KR KR1020167004578A patent/KR101742928B1/ko active Active
- 2012-07-05 ES ES17168574T patent/ES2827231T3/es active Active
- 2012-07-05 PL PL12748547T patent/PL2734549T3/pl unknown
- 2012-07-05 EP EP24200176.6A patent/EP4459282B1/en active Active
- 2012-07-05 DK DK20194926.0T patent/DK3842456T3/da active
- 2012-07-05 HU HUE19196963A patent/HUE068353T2/hu unknown
- 2012-07-05 LT LTEP12748547.2T patent/LT2734549T/lt unknown
- 2012-07-20 UY UY0001034206A patent/UY34206A/es active IP Right Grant
- 2012-07-20 AR ARP120102662A patent/AR087281A1/es active IP Right Grant
2014
- 2014-01-31 ZA ZA2014/00768A patent/ZA201400768B/en unknown
- 2014-06-12 US US14/302,730 patent/US20140286958A1/en not_active Abandoned
- 2014-07-08 US US14/325,541 patent/US9206253B2/en active Active
2016
- 2016-05-30 AU AU2016203590A patent/AU2016203590B2/en active Active
2017
- 2017-08-24 CY CY20171100897T patent/CY1119475T1/el unknown
2018
- 2018-12-05 US US16/210,228 patent/US10421807B2/en active Active
2019
- 2019-08-13 US US16/539,455 patent/US20190389944A1/en not_active Abandoned
- 2019-08-14 US US16/540,483 patent/US10526405B2/en active Active
2020
- 2020-10-09 HR HRP20201634TT patent/HRP20201634T1/hr unknown
- 2020-11-13 CY CY20201101077T patent/CY1123791T1/el unknown

Also Published As

Publication number	Publication date
HUE068353T2 (hu)	2024-12-28
CN105504059A (zh)	2016-04-20
RS66178B1 (sr)	2024-12-31
LT3842456T (lt)	2024-11-11
ES2638340T3 (es)	2017-10-19
DK2734549T3 (da)	2017-09-11
CY1119475T1 (el)	2018-03-07
CA2926379A1 (en)	2013-01-24
EP3842456A1 (en)	2021-06-30
US9206253B2 (en)	2015-12-08
HRP20241388T1 (hr)	2024-12-20
UY34206A (es)	2013-02-28
PL3219729T3 (pl)	2021-01-25
LT3219729T (lt)	2020-11-25
AU2016203590A1 (en)	2016-06-16
AR087281A1 (es)	2014-03-12
CY1123791T1 (el)	2022-03-24
KR20160028488A (ko)	2016-03-11
MX377475B (es)	2025-03-10
FI3653645T3 (fi)	2024-10-25
PT2734549T (pt)	2017-08-29
SI3842456T1 (sl)	2025-03-31
EP2734549A1 (en)	2014-05-28
RS66170B1 (sr)	2024-12-31
EP3653645B1 (en)	2024-08-21
RU2014101250A (ru)	2015-08-27
EP3842456B1 (en)	2024-09-18
ES2993120T3 (en)	2024-12-23
SI2734549T1 (sl)	2017-10-30
CN105504059B (zh)	2020-08-11
RS60924B1 (sr)	2020-11-30
CN103890009B (zh)	2017-02-15
ES2994801T3 (en)	2025-01-31
EP3219729B1 (en)	2020-09-09
JP6022563B2 (ja)	2016-11-09
MX349053B (es)	2017-07-06
PT3842456T (pt)	2024-11-29
CA2842475A1 (en)	2013-01-24
PL2734549T3 (pl)	2017-11-30
PT3219729T (pt)	2020-10-23
AU2012285432B2 (en)	2016-06-16
ES2827231T3 (es)	2021-05-20
US10421807B2 (en)	2019-09-24
LT2734549T (lt)	2017-09-11
US10526405B2 (en)	2020-01-07
US20130022616A1 (en)	2013-01-24
CN103890009A (zh)	2014-06-25
SI3219729T1 (sl)	2020-11-30
BR112014001407A2 (pt)	2017-03-01
PL3653645T3 (pl)	2025-01-13
ME02837B (me)	2018-01-20
HRP20171198T1 (hr)	2017-10-20
KR20140041858A (ko)	2014-04-04
DK4459282T3 (da)	2025-12-08
HUE034282T2 (en)	2018-02-28
EP3653645A1 (en)	2020-05-20
EP2734549B1 (en)	2017-05-24
HRP20201634T1 (hr)	2020-12-25
JP2014529295A (ja)	2014-11-06
US20190092854A1 (en)	2019-03-28
CA2842475C (en)	2018-01-02
FI3842456T3 (fi)	2024-11-12
MX2014000803A (es)	2014-03-31
US8790651B2 (en)	2014-07-29
NZ620031A (en)	2016-03-31
AU2012285432A1 (en)	2014-01-30
SI3653645T1 (sl)	2025-01-31
KR101613024B1 (ko)	2016-04-18
EP3219729A1 (en)	2017-09-20
DK3653645T3 (da)	2024-09-16
HRP20241528T1 (hr)	2025-01-03
HUE051068T2 (hu)	2021-01-28
HUE068973T2 (hu)	2025-02-28
RS56268B1 (sr)	2017-11-30
PL3842456T3 (pl)	2025-01-20
LT3653645T (lt)	2024-10-25
US20140286958A1 (en)	2014-09-25
AU2016203590B2 (en)	2017-12-21
US20190359702A1 (en)	2019-11-28
WO2013011407A1 (en)	2013-01-24
PT3653645T (pt)	2024-11-18
EP4459282A2 (en)	2024-11-06
BR112014001407A8 (pt)	2022-11-08
US20190389944A1 (en)	2019-12-26
US20140315251A1 (en)	2014-10-23
AU2012285432C1 (en)	2016-12-22
KR101742928B1 (ko)	2017-06-01
ZA201400768B (en)	2015-12-23
EP4459282A3 (en)	2025-01-08
EP4459282B1 (en)	2025-10-22

Publication	Publication Date	Title
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
DK4459282T3 (da)	2025-12-08	Monoklonalt interleukin-31-antistof
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
DK2521736T3 (da)	2019-10-28	Humaniserede antistoffer
DK2847231T3 (da)	2019-10-14	Multispecifikke monoklonale antistoffer
HUE036663T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
BR112013022797A2 (pt)	2016-12-06	anticorpos anti-ctla4 humanizados
HRP20180728T1 (hr)	2018-07-27	Humanizirana protutijela koja prepoznaju alfa-sinuklein
HRP20181690T1 (hr)	2018-12-28	Varijante protutijela fc
PL3415531T3 (pl)	2024-02-26	Białka wiążące antygen
IL232053A0 (en)	2014-05-28	Antibody formulations
BR112012030311A2 (pt)	2017-01-24	anticorpo
IL229618B (en)	2018-10-31	Isolated antibody that binds fcrn
LT2742068T (lt)	2019-07-10	Nauji antikūnai prieš fosforilcholiną
CO6841994A2 (es)	2014-01-20	Anticuerpos